Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Effect of PP-01 on Cannabis Withdrawal Syndrome

ClinicalTrials.gov ID: NCT05494437

Public ClinicalTrials.gov record NCT05494437. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 21, 2026, 1:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Multicenter, Randomized, Double-Blind, Multiple-Dose, Placebo Controlled Clinical Trial of Two Doses of PP-01 for the Mitigation of Cannabis Withdrawal Symptoms

Study identification

NCT ID
NCT05494437
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
PleoPharma, Inc.
Industry
Enrollment
234 participants

Conditions and interventions

Interventions

  • Gabapentin Drug
  • Nabilone Drug
  • PP-01 High Dose Combination Product
  • PP-01 Low Dose Combination Product
  • Placebo Drug

Drug · Combination Product

Eligibility (public fields only)

Age range
18 Years to 55 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 26, 2022
Primary completion
Aug 20, 2023
Completion
Aug 20, 2023
Last update posted
Aug 15, 2024

2022 – 2023

United States locations

U.S. sites
18
U.S. states
12
U.S. cities
18
Facility City State ZIP Site status
Behavioral Research Specialists, LLC Glendale California 91206
Synergy San Diego Lemon Grove California 91945
Neuropsychiatric Research Institute Orange California 92868
CNS Clinical Research Group Coral Springs Florida 33067
Gulf Coast Clinical Research Fort Myers Florida 33912
Innovative Clinical Research Inc. Lauderhill Florida 33319
CenExel iResearch Atlanta, LLC Decatur Georgia 30030
CenExel iResearch Savannah, LLC Savannah Georgia 31405
Pillar Clinical Research, LLC Chicago Illinois 60641
Otrimed Research Center Edgewood Kentucky 41017
Tandem Clinical Research Marrero Louisiana 70072
Benchmark Research Shreveport Louisiana 71101
Hassman Research Institute Berlin New Jersey 08009
North Star Medical Research Middleburg Heights Ohio 44130
Pahl Pharmaceutical Professionals LLC Oklahoma City Oklahoma 73112
Medical University of South Carolina Charleston South Carolina 29403
Austin Clinical Trials Austin Texas 78744
Cedar Clinical Research Draper Utah 84020

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05494437, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 15, 2024 · Synced May 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05494437 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →